Tuesday, 23 April 2024

[the_ad_group id="2845"]


Ginkgo Bioworks and Prozomix partner for enzyme innovation in API production By Investing.com

Beamr Imaging IPO Opens at $3.94 After Pricing at $4 By Investing.com

[the_ad id="21475"]


NORTHUMBERLAND, England and BOSTON – Prozomix, a UK-based biotech company, and Ginkgo Bioworks, a US-based cell programming company, have announced a partnership aimed at advancing enzyme development for the manufacture of active pharmaceutical ingredients (APIs).

The collaboration, unveiled today, focuses on combining Ginkgo’s artificial intelligence/machine learning (AI/ML) capabilities with Prozomix’s extensive enzyme sequence data to produce next-generation enzyme plates for API manufacturing.

This partnership also signifies Prozomix’s incorporation into the Ginkgo Technology Network, a consortium of technology partners striving to enhance innovation in customer research and development (R&D) programs. As part of this ecosystem, Ginkgo’s customers will now have access to Prozomix’s scalable contract manufacturing services.

The pharmaceutical industry has been moving towards the use of biocatalysts in API manufacturing, driven by the need for more sustainable supply chains and reduced costs. Prozomix and Ginkgo’s joint effort will utilize AI models informed by enzyme sequences from Prozomix’s libraries and Ginkgo’s metagenomic database to discover novel enzymes. These enzymes will then be used to create new enzyme plates that offer greater diversity and performance, with the potential to catalyze reactions previously unattainable with traditional plates.

The new enzyme plates developed through this collaboration will be made available to pharmaceutical process chemistry groups, with the stipulation that screening data will be shared with Ginkgo, aiding in the continuous refinement of their AI/ML models.

Simon J. Charnock, CEO of Prozomix, expressed confidence that the partnership with Ginkgo will keep Prozomix at the forefront of biocatalyst provision. Cindy Chang, Senior Director of Business Development at Ginkgo Bioworks, highlighted the anticipated benefits of the partnership in meeting cost savings and sustainability goals in API manufacturing.

The announcement of this partnership is based on a press release statement and contains forward-looking statements about the potential capabilities and success of the collaboration. These statements are subject to various risks and uncertainties that could cause actual results to differ materially from expectations.

InvestingPro Insights

As Prozomix and Ginkgo Bioworks embark on their innovative collaboration to enhance enzyme development for pharmaceuticals, it is illuminating to consider the financial…

Click Here to Read the Full Original Article at All News…


[the_ad id="21476"]